4//SEC Filing
Dowden Nathan J 4
Accession 0001689375-24-000004
CIK 0001689375other
Filed
Mar 4, 7:00 PM ET
Accepted
Mar 5, 7:46 PM ET
Size
15.4 KB
Accession
0001689375-24-000004
Insider Transaction Report
Form 4
Dowden Nathan J
President & COO
Transactions
- Award
Common Stock
2024-03-01+33,100→ 81,268 total - Award
Common Stock
2024-03-01+60,000→ 141,268 total - Tax Payment
Common Stock
2024-03-04$12.42/sh−343$4,261→ 140,925 total - Tax Payment
Common Stock
2024-03-04$13.37/sh−409$5,467→ 140,516 total - Tax Payment
Common Stock
2024-03-05$12.28/sh−1,486$18,246→ 139,030 total - Award
Stock Option (Right to Buy)
2024-03-01+50,100→ 50,100 totalExercise: $13.73Exp: 2034-03-01→ Common Stock (50,100 underlying)
Footnotes (7)
- [F1]Represents a grant of restricted stock units ("RSUs") under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs shall vest as follows: (i) 25% on March 1, 2025; (ii) 25% on March 1, 2026; (iii) 25% on March 1, 2027 and (iv) the remaining 25% on March 1, 2028, so long as the Reporting Person remains an employee or other service provider of the Issuer through such date.
- [F2]Represents a grant of restricted stock units ("RSUs") under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs shall vest as follows: (i) 50% on March 1, 2026 and (ii) the remaining 50% on March 1, 2027, so long as the Reporting Person remains an employee or other service provider of the Issuer through such date.
- [F3]This sale represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of previously granted RSUs.
- [F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.10 to $13.08, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F5]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.15 to $13.82, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F6]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.03 to $12.44, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F7]25% of the option shares shall vest and become exercisable on March 1, 2025, with the remaining 75% vesting in thirty-six (36) equal monthly installments thereafter, such that the option shares will be fully vested on March 1, 2028.
Documents
Issuer
Entrada Therapeutics, Inc.
CIK 0001689375
Entity typeother
Related Parties
1- filerCIK 0001873392
Filing Metadata
- Form type
- 4
- Filed
- Mar 4, 7:00 PM ET
- Accepted
- Mar 5, 7:46 PM ET
- Size
- 15.4 KB